We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » COVID-19 Master Protocol Trial Participants Should Be Randomized, FDA Says
COVID-19 Master Protocol Trial Participants Should Be Randomized, FDA Says
Sponsors using master protocols to test new drugs and therapies for treating or preventing COVID-19 should base their analyses on comparisons between control arm participants who were concurrently randomized, the FDA advised in a final guidance released yesterday.